| Turner Syndrome

Humatrope vs Genotropin

Side-by-side clinical, coverage, and cost comparison for turner syndrome.

Deep comparison between: Humatrope vs Genotropin with Prescriber.AI

AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.

Safety signalsGenotropin has a higher rate of injection site reactions vs Humatrope based on FDA-approved prescribing information

Coverage gaps3 major payers require step therapy for Genotropin but not Humatrope, including UnitedHealthcare

Category

Humatrope

Genotropin

At A Glance

RouteSC injection

FrequencyDaily

ClassRecombinant human growth hormone

RouteSC injection

Frequency6-7 times weekly

ClassRecombinant human growth hormone

Indications

Somatotropin deficiency
Turner Syndrome
Short Stature Homeobox Deficiency
Growth retardation

Somatotropin deficiency
Prader-Willi Syndrome
Growth failure
Turner Syndrome
Growth Disorders

Dosing

Somatotropin deficiency (pediatric) 0.18 mg/kg/week to 0.3 mg/kg/week divided into equal doses given 6 or 7 days per week by SC injection.

Somatotropin deficiency (adult) Non-weight based: initiate at approximately 0.2 mg/day (range 0.15-0.3 mg/day), increase every 1-2 months by 0.1-0.2 mg/day per patient requirements; weight-based (not for obese patients): initiate at 0.006 mg/kg/day up to 0.0125 mg/kg/day; daily SC injection.

Turner Syndrome Up to 0.375 mg/kg/week divided into equal doses given 6 or 7 days per week by SC injection.

Short Stature Homeobox Deficiency 0.35 mg/kg/week (0.05 mg/kg/day) by SC injection.

Growth retardation Idiopathic Short Stature: up to 0.37 mg/kg/week; Small for Gestational Age: up to 0.47 mg/kg/week; divided into equal doses given 6 or 7 days per week by SC injection.

Somatotropin deficiency (pediatric) 0.16 to 0.24 mg/kg/week SC, divided into 6-7 subcutaneous injections.

Prader-Willi Syndrome 0.24 mg/kg/week SC, divided into 6-7 subcutaneous injections.

Turner Syndrome 0.33 mg/kg/week SC, divided into 6-7 subcutaneous injections.

Growth Disorders Up to 0.47 mg/kg/week SC (idiopathic short stature), divided into 6-7 subcutaneous injections.

Growth failure Up to 0.48 mg/kg/week SC (born small for gestational age), divided into 6-7 subcutaneous injections.

Somatotropin deficiency (adult) Non-weight based: starting ~0.2 mg/day SC (range 0.15-0.30 mg/day), titrated by 0.1-0.2 mg/day increments; weight based: starting up to 0.04 mg/kg/week SC, titrated to up to 0.08 mg/kg/week.

Contraindications

Acute critical illness after open heart surgery, abdominal surgery, multiple accidental trauma, or acute respiratory failure
Prader-Willi syndrome in pediatric patients who are severely obese, have a history of upper airway obstruction or sleep apnea, or have severe respiratory impairment
Active malignancy
Known hypersensitivity to somatropin or any excipient in HUMATROPE
Active proliferative or severe non-proliferative diabetic retinopathy
Closed epiphyses in pediatric patients

Acute critical illness due to complications following open heart surgery, abdominal surgery, multiple accidental trauma, or acute respiratory failure
Prader-Willi syndrome with severe obesity, history of upper airway obstruction or sleep apnea, or severe respiratory impairment
Active malignancy
Known hypersensitivity to somatropin or any excipient
Active proliferative or severe non-proliferative diabetic retinopathy
Closed epiphyses (for growth promotion in pediatric patients)

Drug Interactions

267View drug interactions

Adverse Reactions

Most common (>=5%) Edema, arthralgia, paresthesia, myalgia, pain, peripheral edema, headache, hypertension, rhinitis, back pain (adults); hypothyroidism, allergic reaction, arthralgia, bone disorder, injection site pain (pediatric GHD).

Serious Increased mortality in acute critical illness, fatalities in Prader-Willi syndrome, neoplasms, glucose intolerance and diabetes mellitus, intracranial hypertension, severe hypersensitivity, fluid retention, hypoadrenalism, hypothyroidism, slipped capital femoral epiphysis, scoliosis progression, pancreatitis, lipoatrophy.

Postmarketing Anaphylactic reactions, angioedema, increase in size or number of cutaneous nevi, gynecomastia, pancreatitis, new-onset type 2 diabetes mellitus, osteonecrosis, leukemia.

Most common (>=5%) Peripheral swelling, arthralgia, upper respiratory infection, pain in extremities, peripheral edema, paresthesia, headache, stiffness of extremities, fatigue (reported in adult GHD clinical trials at or above 5% threshold)

Postmarketing Serious systemic hypersensitivity reactions including anaphylaxis and angioedema, leukemia, new-onset type 2 diabetes mellitus, slipped capital femoral epiphysis, osteonecrosis/avascular necrosis, carpal tunnel syndrome

Pharmacology

Somatropin is a recombinant human growth hormone that binds dimeric GH receptors on target tissue cell membranes, triggering intracellular signal transduction and induction of GH-dependent proteins (IGF-1, IGFBP-3, acid-labile subunit), with direct and IGF-1-mediated effects including stimulation of chondrocyte differentiation and proliferation, hepatic glucose output, protein synthesis, and lipolysis, thereby promoting skeletal and linear growth in pediatric patients with GH deficiency.

Somatropin, a recombinant human growth hormone therapeutically equivalent to pituitary-derived GH, stimulates linear growth in pediatric patients through effects on epiphyseal plates, normalizes IGF-I concentrations in GHD and Prader-Willi syndrome, and in adults reduces fat mass and increases lean body mass with favorable lipid metabolic changes.

View Full FDA Information

View full FDA information

Enter your patient's insuranceCheck specific coverage details for your patient.

Most Common Insurance

Anthem BCBS

Humatrope